AVROBIO

AVROBIO

AVROBIO

Clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
Raised
$184.7M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
$99,700,000
IPO - 2018
$60,000,000
Venture capital (Series B) - 2018
Atlas Venture Aisling Capital Clarus Ventures +12
Team Size
1–10
Employees
$99,700,000 IPO
PE HUB

VC-backed Avrobio rolls out IPO

Stock markets Health
$60,000,000 Venture capital (Series B)
FinSMEs , Xconomy , MedCity News

Avrobio Raises $60M in Series B Financing

Health Funding
$25,000,000 Venture capital (Series A)
businesswire

AVROBIO, Inc. Announces $25 Million Series A Financing to Advance Novel, Clinical-Stage Gene Therapies for Rare Diseases...